US Glioma Diagnosis Treatment Market

ID: MRFR/Pharma/17379-HCR
100 Pages
Vikita Thakur
Last Updated: May 13, 2026
US Glioma Diagnosis and Treatment Market Research Report By Type (Primary Tumors, Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, Recurrent High Grade Glioma), By Location (Supratentorial, Infratentorial) and By End User (Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, Others) - Growth & Industry Forecast 2025 To 2035
US Glioma Diagnosis Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.2%
2024 Market Size$ 876.33 Million
2025 Market Size$ 921.9 Million
2035 Market Size$ 1,530.86 Million
Key Players
Roche
Novartis
Merck
Bristol-Myers Squibb
Eli Lilly
Amgen
Trends
  • Advancements in Diagnostic Imaging
  • Rise of Targeted Therapies
  • Increased Collaboration and Research Funding
Opportunities
  • Growing Incidence of Glioma Cases
  • Rising Investment in Cancer Research
  • Regulatory Support for Innovative Therapies
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Construction, BY Type (USD Million) | |
      1. 4.1.1 Primary Tumors | |
      2. 4.1.2 Secondary Tumors |
    2. 4.2 Construction, BY Diagnosis (USD Million) | |
      1. 4.2.1 Neurological Exam | |
      2. 4.2.2 CT Scan | |
      3. 4.2.3 MRI | |
      4. 4.2.4 PET Scan | |
      5. 4.2.5 Biopsy | |
      6. 4.2.6 Molecular Testing | |
      7. 4.2.7 EEG | |
      8. 4.2.8 Others |
    3. 4.3 Construction, BY Treatment (USD Million) | |
      1. 4.3.1 Surgery | |
      2. 4.3.2 Chemotherapy | |
      3. 4.3.3 Radiation Therapy | |
      4. 4.3.4 Immunotherapy | |
      5. 4.3.5 Targeted Therapy |
    4. 4.4 Construction, BY Grade (USD Million) | |
      1. 4.4.1 Low Grade Glioma | |
      2. 4.4.2 High Grade Glioma | |
      3. 4.4.3 Recurrent High Grade Glioma |
    5. 4.5 Construction, BY Location (USD Million) | |
      1. 4.5.1 Supratentorial | |
      2. 4.5.2 Infratentorial |
    6. 4.6 Construction, BY End User (USD Million) | |
      1. 4.6.1 Hospitals & Clinics | |
      2. 4.6.2 Diagnostic Centers | |
      3. 4.6.3 Medical Research Centers | |
      4. 4.6.4 Others 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Construction | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Roche (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Novartis (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Merck (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Bristol-Myers Squibb (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Eli Lilly (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Amgen (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 AstraZeneca (GB) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Pfizer (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Bayer (DE) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY TYPE |
    6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT |
    8. 6.5 US MARKET ANALYSIS BY GRADE |
    9. 6.6 US MARKET ANALYSIS BY LOCATION |
    10. 6.7 US MARKET ANALYSIS BY END USER |
    11. 6.8 KEY BUYING CRITERIA OF CONSTRUCTION |
    12. 6.9 RESEARCH PROCESS OF MRFR |
    13. 6.10 DRO ANALYSIS OF CONSTRUCTION |
    14. 6.11 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
    15. 6.12 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
    16. 6.13 SUPPLY / VALUE CHAIN: CONSTRUCTION |
    17. 6.14 CONSTRUCTION, BY TYPE, 2024 (% SHARE) |
    18. 6.15 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million) |
    19. 6.16 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE) |
    20. 6.17 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million) |
    21. 6.18 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE) |
    22. 6.19 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million) |
    23. 6.20 CONSTRUCTION, BY GRADE, 2024 (% SHARE) |
    24. 6.21 CONSTRUCTION, BY GRADE, 2024 TO 2035 (USD Million) |
    25. 6.22 CONSTRUCTION, BY LOCATION, 2024 (% SHARE) |
    26. 6.23 CONSTRUCTION, BY LOCATION, 2024 TO 2035 (USD Million) |
    27. 6.24 CONSTRUCTION, BY END USER, 2024 (% SHARE) |
    28. 6.25 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million) |
    29. 6.26 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    30. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    31. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million) | |
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million) | |
      4. 7.2.4 BY GRADE, 2025-2035 (USD Million) | |
      5. 7.2.5 BY LOCATION, 2025-2035 (USD Million) | |
      6. 7.2.6 BY END USER, 2025-2035 (USD Million) |
    32. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    33. 7.4 ACQUISITION/PARTNERSHIP | |

US Glioma Diagnosis Treatment Market Segmentation

US Glioma Diagnosis Treatment Market By Type (USD Million, 2025-2035)

  • Primary Tumors
  • Secondary Tumors

US Glioma Diagnosis Treatment Market By Diagnosis (USD Million, 2025-2035)

  • Neurological Exam
  • CT Scan
  • MRI
  • PET Scan
  • Biopsy
  • Molecular Testing
  • EEG
  • Others

US Glioma Diagnosis Treatment Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy

US Glioma Diagnosis Treatment Market By Grade (USD Million, 2025-2035)

  • Low Grade Glioma
  • High Grade Glioma
  • Recurrent High Grade Glioma

US Glioma Diagnosis Treatment Market By Location (USD Million, 2025-2035)

  • Supratentorial
  • Infratentorial

US Glioma Diagnosis Treatment Market By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Medical Research Centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.